- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$80.59 BnMarket Estimate, 2026
$83.97 BnMarket Forecast, 2034
$116.70 BnCAGR, 2026–2034
4.2%Asia Pacific Radioimmunoassay Market Size, Share, Trends & Forecast (2026-2034)
- Market Scope: Comprehensive healthcare industry intelligence tracking radioimmunoassay (RIA) markets across reagents and kits, automated analyzers, clinical and pharmaceutical research end-user sectors, and localized country frameworks in the Asia-Pacific region.
- Market Valuation: Valued at USD 80.59 billion in 2025, estimated at USD 83.97 billion in 2026, and projected to reach USD 116.70 billion by 2034, growing at a steady CAGR of 4.2% from 2026 to 2034.
- Primary Growth Drivers: High regional prevalence of chronic, infectious, and lifestyle-related conditions (such as cardiovascular diseases, endocrine disorders, and cancer), increasing demand for healthcare automation and high-throughput diagnostic procedures, and rising healthcare investments for research and development.
Key Asia-Pacific Radioimmunoassay Segment Metrics (2026–2034)
| Category | Leading Segment (2025 Position) | Fastest-Growing Segment |
|---|---|---|
| By Type | Reagents and Kits (primary consumables driving regular diagnostic testing, hormone profiling, and infectious disease screening) | Analyzers (expanding due to higher laboratory automation and error-free high-throughput requirements) |
| By End User | Hospitals & Clinical Diagnostic Laboratories (core hubs managing mass patient screening and pathology services) | Pharmaceutical Industry and CROs (driven by drug screening and personalized medicine development trials) |
| By Application | Clinical Diagnostics (dominant sector handling infectious diseases, endocrinology, oncology, and cardiology assays) | Research Applications (propelled by biomarker quantification and advanced biomedical studies) |
| By Region / Country | China (holding the largest regional market share backed by advanced medical facilities and strong government support) | Japan and India (experiencing accelerated uptake due to aging populations, high chronic disease burdens, and R&D investments) |
Major Industry Players & Market Structure
Market Structure: Competitive regional landscape featuring prominent global life science corporations and specialized diagnostic players competing on product precision, assay sensitivity, automation integration, and robust regional distribution networks.
Key Market Players: DIAsource ImmunoAssays SA, Beckman Coulter, IBL International, PerkinElmer, DRG International, MP Biomedicals LLC, Cisbio, Euro Diagnostica AB, DiaSorin S.p.A., EMD Millipore, Izotop, Berthold Technologies GmbH & Co. KG, and STRATEC Biomedical AG.
Download Free Sample Report
Asia Pacific Radioimmunoassay Market Size
The Asia Pacific radioimmunoassay market size was valued at USD 80.59 billion in 2025 and is anticipated to reach USD 83.97 billion in 2026 from USD 116.70 billion by 2034, growing at a CAGR of 4.2% during the forecast period from 2026 to 2034.
Applications of radioimmunoassay can be used for infectious diseases, toxicology, neonatal analysis oncology, endocrinology, cardiology, hematology and blood tests, bone and mineral disorders, and autoimmune disorders. This increasing prevalence of diseases, which require technologically advanced products for diagnosis, is responsible for driving the growth of the APAC radioimmunoassay market during the forecast period.
In the biotechnology and pharmaceutical industry, radioimmunoassay is used for drug screening. However, the need for personalized diagnostics and treatment will drive the market in the future. For instance, the World Health Organization (WHO) reports indications that around 36% of nutritional deficiencies, 38% of perinatal conditions, 31% of respiratory disease, 34% of maternal conditions infections, and 28% of the global burden of infectious diseases and parasitic diseases are widespread in this region. APAC regions have seen a rapid increase in cardiovascular diseases (CVD) in the past several years. According to the Australian Government Department of Health and Aged Care, one in six Australians suffers from CVD, representing more than 4 million Australians. This indicates that approximately 16.7% of Australians live with CVD. Among Korean adult patients, the prevalence of clinically diagnosed CVD per 1000 people was reported to be 101.11 in 2015 and 103 in 2016. In the Japanese population, the death rate from CVD among the age group above 80 fell from 2.25% in 1966 to 0.95% in 2018, while the death rate among 90-year-olds fell from 4.75% in 1965 to 0. 96% in 2017.
In addition, the growing demand for healthcare automation and high throughput procedures in diagnostic laboratories and research centers to ensure customer and patient satisfaction with error-free results or misinterpretation are other factors that lead to the growth of the APAC radioimmunoassay market over the forecast period.
However, an alternative method to immunoassay for detecting biomolecules poses a challenge to the growth of the APAC radioimmunoassay market. Moreover, the high cost of the equipment required for the procedures and the hazardous, radioactive material are estimated to hamper the market's growth.
Geographically, Asia-Pacific is projected to experience a healthy growth rate during the forecast period, owing to the large population vulnerable to various chronic diseases and increasing healthcare facilities. China led the APAC market in 2023 and is forecasted to continue the APAC market throughout the forecast period due to the increasing adoption of technologically advanced devices, public awareness, high infection rates, better medical facilities, and increasing adoption of innovative products. In addition, government support and understanding are also increasing the growth of the Chinese market.
During the forecast period, the Japanese market is also estimated to grow at a promising CAGR. Furthermore, the market in this region is anticipated to witness significant growth during the forecast period, owing to the increasing prevalence of various infectious diseases and cancer, along with substantial investments in healthcare for research and development.
KEY MARKET PLAYERS
Companies playing a notable role in the Asia Pacific RIA market include
- DIAsource ImmunoAssays SA
- Beckman Coulter
- IBL International
- PerkinElmer
- DRG International
- MP Biomedicals LLC
- Cisbio
- Euro Diagnostica AB
- DiaSorin S.p.A.
- EMD Millipore
- Izotop
- Berthold Technologies GmbH & Co. KG
- STRATEC Biomedical AG
MARKET SEGMENTATION
This research report on the Asia Pacific Radioimmunoassay Market has been segmented and sub-segmented into the following categories
By Type
- Reagents and Kits
- Analyzers
By End User
- Hospitals
- Pharmaceutical Industry and CRO
- Clinical Diagnostic Laboratories
By Application
- Research
- Clinical Diagnostics
By Country
- India
- China
- Japan
- South Korea
- Australia
- New Zealand
- Thailand
- Malaysia
- Vietnam
- Philippines
- Indonesia
- Singapore
- Rest of APAC